Clinical trials: Pediatric Growth Hormone Deficiency

Pediatric Growth Hormone Deficiency

Versartis Long-Term Safety Study of Somavaratan

• Terminated
• Age: 3 years and older
• Phase 2/3
• Injection or infusion

Protocol 13VR3 is is a multi-center, open-label study assessing long-term somavaratan administration. Patients will be monitored for safety throughout their participation in the study.

Trial name

VISTA (NCT02068521)

Testing

somavaratan

Volunteers

385 people

Sponsor

Versartis Inc.